Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

NET4CGD · Gene Therapy for X-linked Chronic Granulomatous Disease (CGD)

FP7Status: CLOSED1 December 201231 May 2018EU funding €5,999,607

This project is focused on the clinical development of a new orphan drug that can rapidly become a new treatment option for patients with the X-linked form of chronic granulomatous disease (X-CGD). This rare primary immune deficiency of phagocytes is caused by mutations in the gp91phox gene. Affected patients are highly-susceptible to infections and develop inflammatory granulomas. Several members of the Net4CGD consortium have already attempted hematopoietic gene correction of X-CGD using gp91 gammaretroviral gene transfer vectors. While functional correction and clinical benefit was initially achieved, problems arose, linked to insertional mutagenesis, vector silencing and lack of long-term engraftment. Net4CGD proposes future trials to achieve (i) effective transduction of hematopoietic cells, (ii) physiological expression of the transgene and (iii) long-term engraftment of gene modified cells. A new lentiviral vector (LV) was developed to express gp91phox in myeloid cells. Encouraging results obtained in preclinical studies and through the compassionate treatment of a patient, prompt us to test the LV in a multi-center study in several European centers expert in CGD, under the sponsorship of a rare disease specialist. The tasks include i) Manufacturing clinical grade vector to support clinical studies, ii) Conducting a multi-center phase I/II trial in eligible X-CGD patients, with LV gene-modified autologous hematopoietic stem cells to evaluate the safety and efficacy of the procedure iii) Ensuring high-quality and harmonization of products and procedures to facilitate future product registration iv) Obtaining state-of-the art information on biological efficacy and safety in patients by assessing immune restoration and large-scale integrome data. If positive, this study will be used to register the orphan drug. The treatment is expected to improve patients’ quality of life and will reduce the economical burden of CGD. Results should benefit other RD.

Consortium · 11 organisations

coordinator

ASSOCIATION GENETHON

FR · €2,250,140

participant

BIONTECH INNOVATIVE MANUFACTURING SERVICES GMBH

DE · €751,808

participant

EUROFINS GENOMICS EUROPE PHARMA AND DIAGNOSTICS PRODUCTS & SERVICES SANGER PCR GMBH

DE · €240,096

participant

GENOSAFE SAS

FR · €852,000

participant

ASSISTANCE PUBLIQUE HOPITAUX DE PARIS

FR · €350,455

participant

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG

DE · €300,000

participant

FINOVATIS

FR · €125,000

participant

KLINIKUM DER JOHANN WOLFGANG VON GOETHE UNIVERSITAET

DE · €110,250

participant

University of Zurich

CH · €300,000

participant

UNIVERSITY COLLEGE LONDON

€449,858

participant

CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG-SPEYER-HAUS STIFTUNG

DE · €270,000

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.